Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990979 | 0.76 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL1344880 | 0.76 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL669511 | 0.75 | CRBN (0.42) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL17205220 | 0.75 | CRBN (0.38) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL3993881 | 0.73 | CRBN (0.45) | CRBNDDB1POLBHSD17B10DUT | |
| SCHEMBL27480972 | 0.71 | CRBN (0.46) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL5290093 | 0.71 | CRBN (0.46) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL2719765 | 0.71 | CRBN (0.54) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL10642564 | 0.71 | CRBN (0.48) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL669608 | 0.70 | CYP17A1 (0.39) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 584 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2294076-B1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED REPLICATION OF NUCLEIC ACID | TRILINK BIOTECHNOLOGIES (US) | 2017-03-08 | — | — | EP | claimed |
| EP-2294076-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TriLink BioTechnologies (US) | 2011-03-16 | — | — | EP | claimed |
| US-20100003724-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TriLink Bio Technologies | 2010-01-07 | — | — | US | claimed |
| WO-2009151921-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TRILINK BIOTECHNOLOGIES (US) | 2009-12-17 | — | — | WO | claimed |
| US-20090011488-A1 | METHODS FOR STORING COMPOSITIONS USEFUL FOR SYNTHESIZING NUCLEIC ACID MOLECULES | ROSETTA INPHARMATICS, LLC (US) | 2009-01-08 | — | — | US | claimed |
| US-20250333473-A1 | CELLS LACKING B2M SURFACE EXPRESSION AND METHODS FOR ALLOGENEIC ADMINISTRATION OF SUCH CELLS | HARVARD COLLEGE (US) | 2025-10-30 | — | — | US | disclosed |
| US-12357675-B2 | Efficient protein expression in vivo using modified RNA (mod-RNA) | THE GENERAL HOSPITAL CORPORATION | 2025-07-15 | — | — | US | disclosed |
| US-12180263-B2 | Cells lacking B2M surface expression and methods for allogeneic administration of such cells | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240335551-A1 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | OLIX US, INC. | 2024-10-10 | — | — | US | disclosed |
| US-12054748-B2 | Mammalian somatic cell with modified RNA encoding reprogramming factors | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| EP-1339699-A1 | SUBSTITUTED AMIDOALKYL URACILS AND THE USE THEREOF | Bayer Aktiengesellschaft (DE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1303497-A1 | SUBSTITUTED AMIDOALKYL-URACILS AS PARP INHIBITORS | Bayer Aktiengesellschaft (DE) | 2003-04-23 | — | — | EP | disclosed |
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | disclosed |
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002040455-A8 | SUBSTITUTED AMIDOALKYL URACILS AND THEIR USE AS INHIBITORS OF THE POLY(ADP-RIBOSE) SYNTHETASE (PARS) | BAYER AG (DE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002040455-A1 | SUBSTITUTED AMIDOALKYL URACILS AND THEIR USE AS INHIBITORS OF THE POLY(ADP-RIBOSE) SYNTHETASE (PARS) | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002006247-A8 | SUBSTITUTED AMIDOALKYL-URACILS AS PARP INHIBITORS | BAYER AG (DE) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002006247-A1 | SUBSTITUTED AMIDOALKYL-URACILS AS PARP INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | CRBN 3966/4885DDB1 1849/4885PKM 2664/4885 |
| US-20240335551-A1 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | FGB, SELP, PTMS | CRBN 1185/4885DDB1 3723/4885PKM 1524/4885 |
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | UNG, UMPS, TYMP | CRBN 4595/4885DDB1 58/4885PKM 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.